News

NaDCC: 1st product to pass EPA efficacy test protocol

New Jersey:  Dry surface biofilm has been found to exist on 93% of all critical care area hospital surfaces. Over 50% of these biofilms contain Mutant Germs which are resistant to antibiotics resulting in hospital acquired infections (HAIs)

The EPA has this week registered the first product to be effective against these biofilms.

Medentech are announcing the efficacy of their effervescent NaDCC disinfection tablet for cleaning and disinfection.

Michael Gately CEO Medentech: “This is something I might never see in my lifetime again. Biofilms give germs 1,000 times more protection, thus standard disinfectants such as bleach, hydrogen peroxide, or ultraviolet light, don’t work properly. The EPA has developed a new efficacy protocol and I am delighted to say that our NaDCC effervescent disinfection tablets are the first and only product to have passed this test”.

 

About Dry Surface Biofilm

Most germs on hospital surfaces live in a biofilm. A biofilm comprises any group of microorganisms in which cells stick to a surface. These adherent cells become embedded within a slimy extracellular matrix. Following initial research by Professor Karen Vickery, Hu et al have evidenced the existence of biofilm on 93% of all critical care area surfaces with over 50% of these containing mutant germs.

 About HAIs & Multi Drug Resistant Bacteria

Mutant germs are multi drug resistant organisms which cause HAIs. Approximately 722,000 HAIs occur annually in U.S. acute care hospitals resulting in 75,000 deaths (CDC 2014).

 About the Solution:

A new tool has emerged as a broad-spectrum cleaner & disinfectant that eliminates pathogens without damaging surfaces.  

Klorkleen 2 disinfectant is the first product to receive EPA registration for its Biofilm efficacy (EPA  71847-7).  Klorkleen 2 is a powerful surface disinfectant based on sodium dichloroisocyanurate (NaDCC) with registered claims as a hospital grade disinfectant that meets the surface disinfection requirements of OSHA Bloodborne Pathogens Standards. Kill claims include Clostridium difficile spores, Norovirus, Tb, CRE.

 

 By Mark Hodgson

Aug 14 2018 

New revelation about hospital bed sheets –

transmission vector for dry surface biofilm

 

Recent work by a research group at Macquarie University in Australia have highlighted some startling findings regarding hospital bed sheets.

Previous work by this research group has shown that dry surface biofilm is present on up to 93% of hospital surfaces, with over half of these biofilms containing multiple drug resistant organisms. One such surface that may harbour dry surface biofilm are the patient mattresses. This is exacerbated by the fact that patients continually shed microorganisms into their immediate environment.

Researchers found that pathogenic bacteria grown in a dry surface biofilm could be transferred through cotton sheets at rates of 100 – 1000 cells up to 20 consecutive times. This could potentially aid the spread of pathogens in a hospital setting, highlighting the importance of mattress cleaning and disinfection.

Only one product has been approved by the US EPA as being effective against healthcare associated biofilms, Medentech’s Klorkleen 2.

 

For more information contact:

Mark Hodgson: mhodgson(at)medentech.com

To top

For more information contact:

info(at)medentech.com